Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab

Abstract

Fig. 1. Rapid clinical response of hidradenitis suppurativa (HS) to secukinumab treatment. Clinical images of the genital and gluteal region (A) before and (B) after 8 weeks of treatment with the interleukin-17A antibody secukinumab, demonstrating rapid reduction in inflammatory nodules and signs of cutaneous inflammation.

Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm

“…Evidence is lacking for other biologic therapies, and any clinical decisions should be based on close monitoring and risk: benefit assessments (66). Recent studies showed administration of other biologics such as other TNF-alpha blockers (66, [90][91][92], ustekinumab, (93-96) secukinumab, (97,98) bimekizumab, (99) canakinumab, (3, 100) apremilast, (1,101) anakinra, (102) guselkumab (103,104), and rituximab (105) in management of HS.…”

T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities

“…Of the IL‐17 neutralizing monoclonal antibodies seculinumab, ixekuzumab and brodalumab, only seculinumab has been approved for the treatment of psoriasis and psoriatic arthritis . It has recently been reported that HS exhibits a clinical response to seculinumab . Current therapeutic efforts focus on attenuating IL‐17 signalling in HS …”

“…[217][218][219] It has recently been reported that HS exhibits a clinical response to seculinumab. 220,221 Current therapeutic efforts focus on attenuating IL-17 signalling in HS. 133,222,223…”

Update on Hidradenitis Suppurativa (Part I): Epidemiology, Pathogenesis, Severity assessment and Comorbidities

“…102 Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17a antibody secukinumab was recently reported. 103 A successful response was also reported with the monoclonal antibody anti-CD20 rituximab (two courses of 200 mg) in a patient with idiopathic carpotarsal osteolysis and chronic active antibody-mediated rejection. 104 Investigations are currently ongoing or recruiting for diverse biologic agents, such as CJM112 (a fully human anti-IL-17A mAb [NCT02421172]) and MABp1 (human anti-IL-1a antibody in patients with HS refractory to adalimumab [NCT02643654]).…”